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Feline lower urinary tract disease (FLUTD) is a common 
clinical entity in domestic cats, accounting for up to 13% 
of cats presented to primary veterinary care.1–3 Cats with 
any disease of the lower urinary tract present with simi-
lar clinical signs (dysuria, haematuria, pollakiuria, inap-
propriate urination), regardless of the aetiology. Very 
often, no causative aetiology can be identified and after 
excluding uroliths, bacterial infections and neoplasia, 
cats are diagnosed with idiopathic FLUTD or feline idi-
opathic cystitis (FIC). In 55–69% of cats FIC is responsi-
ble for FLUTD.1,4,5 Obstructive FLUTD is a feline 
emergency with an excellent outcome and, with proper 
care, a survival rate >90%.6 However, recurrent urethral 
obstruction (rUO) occurs in up to 58% of cats,7 which is a 
financial and psychological imposition on the owner and 
can lead to euthanasia of the cat instead of further 
medical or surgical treatment. In several studies, the 
majority of rUO were identified within in the first week 
of catheter removal.8–10
Inflammation is associated with release of substances 
(eg, eicosanoids, histamines, kinins, serotonin, prosta-
glandins) that mediate pain perception in the central 
nervous system (CNS) via stimulation of nociceptors 
Evaluation of meloxicam for the 
treatment of obstructive feline 
idiopathic cystitis
Roswitha Dorsch1, Friederike Zellner1, Bianka Schulz1,  
Carola Sauter-Louis2 and Katrin Hartmann1
Abstract
Objectives The aim of the study was to investigate the effect of the non-steroidal anti-inflammatory drug meloxicam 
on the clinical course of obstructive idiopathic cystitis in cats in a placebo-controlled clinical study.
Methods Thirty-seven cats with obstructive idiopathic cystitis were enrolled. Cats received supportive treatment 
and an indwelling transurethral catheter for 48 h. On days 0 and 1, all cats received buprenorphine 0.01 mg/kg 
subcutaneously every 8 h. On day 1, cats were randomly assigned to the meloxicam (n = 18) or placebo group 
(n = 19) and received meloxicam (0.1 mg/kg on day 1, 0.05 mg/kg on days 2–5) or placebo orally for five consecutive 
days. Cats were monitored by repeated physical examinations and urinalysis, and with a 5 day questionnaire filled 
in by the owners after discharge and a telephone interview 3 months after presentation. Parameters for evaluation 
of treatment success were the occurrence of recurrent urethral obstruction, results of physical examinations and 
questionnaires.
Results Recurrent urethral obstruction occurred in 4/18 cats (22%) in the meloxicam group and 5/19 cats (26%) 
in the placebo group (P = 1.000). General demeanour and pain on abdominal palpation during hospitalisation 
improved significantly in both groups (P <0.001). After discharge, with regard to general demeanour, food intake 
and voiding behaviour, there were no significant differences within or between groups at different time points.
Conclusions and relevance Orally administered meloxicam for 5 days did not influence the incidence of recurrent 
urethral obstruction and the recovery from clinical signs in cats with obstructive feline idiopathic cystitis. The 
persistence of clinical signs in most of the cats 1 week after initial presentation indicates that symptomatic treatment 
for a longer period of time is warranted.
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and conduction via afferent fibres. Increased numbers of 
mast cells have been identified in cats with idiopathic 
cystitis and are thought to be involved in the pathogen-
esis.11 The effect of inflammatory doses of prednisolone 
on the course of disease has been investigated in a pro-
spective study, but no difference in response has been 
seen between cats treated with prednisolone and cats 
treated with placebo.12 Non-steroidal anti-inflammatory 
drugs (NSAIDs) are widely used by veterinarians for 
this disease. A beneficial effect has not been identified in 
two retrospective studies including cats with non-
obstructive FIC and obstructive FIC, respectively.13,14 
However, the effect of NSAIDs has not yet been evalu-
ated in a prospective trial.
NSAIDs inhibit the activity of cyclooxygenases (COX) 
and decrease the synthesis of prostaglandins. Meloxicam 
is an NSAID of the oxicam group with weak selectivity 
for COX-2. COX-1 is the predominantly constitutively 
produced enzyme that is present in almost all body tis-
sues, whereas COX-2 is predominantly inducible and 
highly upregulated in areas of inflammation,15 and con-
stitutively produced along with COX-1 in the CNS, the 
kidney, vascular endothelium, reproductive tract and 
gastrointestinal tract.16–18 Therefore, the anti-inflamma-
tory and analgesic effect could, theoretically, be benefi-
cial in cats suffering from FIC.
The aim of this prospective, placebo-controlled study 
was to evaluate the effect of meloxicam on the incidence 




The study had a prospective, double-blind, placebo-con-
trolled randomised design and included 37 cats with 
obstructive FIC. Initially, cats with either non-obstruc-
tive (n = 13) or obstructive (n = 37) FIC were included in 
the study. As the majority of cats suffered from obstruc-
tive FIC, only cats with obstructive FIC were evaluated, 
to create a more uniform study population. The study 
medication (meloxicam and placebo) was provided by 
the manufacturer in identical-looking numbered bottles 
in a liquid formulation. The placebo and meloxicam 
looked identical and were indistinguishable. Cats 
enrolled into the study were sequentially numbered and 
received the medication with the same number. All cats 
were treated at the Clinic of Small Animal Medicine, 
LMU, Munich, from November 2006 to August 2008. 
The study was conducted according to German animal 
welfare law. Informed owner consent was obtained from 
all owners before inclusion of cats into the study.
Patients
Cats with clinical signs of FLUTD, such as stranguria, 
haematuria, pollakiuria or painful voiding, and a 
diagnosis of FIC were included in the study. Urethral 
obstruction was assumed if cats had a history of unsuc-
cessful attempts to void and a large, tense and painful 
urinary bladder on abdominal palpation. To properly 
classify the cats as having FIC, urinalysis, including urine 
specific gravity (USG), dipstick, urine sediment and urine 
culture, was performed along with abdominal radio-
graphs and ultrasound of the urinary tract to identify 
urolithiasis and evidence of neoplasia, which led to 
exclusion from the study. All cats were tested for feline 
immunodeficiency virus and feline leukaemia virus, and 
a total thyroxine was measured in all cats older than 
8 years. Cats were also excluded if other diseases, such as 
diabetes mellitus or hyperthyroidism, were identified, or 
if they had been treated with steroids, antimicrobial 
drugs, or NSAIDs in the 2 weeks before presentation. 
Cats were retrospectively withdrawn from the study if 
they had a positive urine culture.
Urinalyses were performed on presentation, 48–60 h 
after presentation and at the recheck examination 
14–21 days later. Urine samples were collected by trans-
cutaneous cystocentesis. A hand refractometer (Atago) 
was used to determine USG. The urine was then ana-
lysed with reagent strips (Combur-9; Roche Diagnostics). 
After centrifugation at 2000 rpm (672 g) for 5 mins, the 
urine sediment was examined microscopically. The 
number of red blood cells (RBC) per high power field 
(HPF) and white blood cells (WBC)/HPF were catego-
rised as follows: RBC/HPF (<10, 10–24, 25–100, >100), 
WBCs/HPF (0–3, 4–6, 7–19, 20–50, >50).
Initial treatment
On admission (day 0), intravenous (IV) fluid therapy with 
a low potassium volume replacement solution (Lactated 
Ringer’s solution) was started. All of the cats received IV 
fluids and buprenorphine and as soon as they were clini-
cally stable, an indwelling urinary catheter (silicon feed-
ing tube, CH 4.5, 1.0 × 1.5 mm; Braun) was inserted 
aseptically under anaesthesia. Administered type and vol-
ume of IV fluid therapy was adjusted based on the degree 
of dehydration, plasma electrolyte concentrations, and the 
severity of postobstructive diuresis. All cats received 0.010 
mg/kg buprenorphine (Temgesic; Essex Pharma GmbH) 
at the time of admission and every 8 h subcutaneously for 
a period of 2 days. In cats that presented with postrenal 
azotaemia, metabolic acidosis or hyperkalaemia, serum 
chemistry and blood gas analysis were repeated after 24 h 
before starting study medication (day 1).
After 36–48 h (day 2), the transurethral catheter was 
removed. Before removal, a urine sample for routine 
analysis and for aerobic bacterial culture was taken. The 
cats were watched for their voiding behaviour after-
wards and remained hospitalised until they were able to 
void spontaneously for 24 h. If cats showed attempts to 
urinate but these attempts were unsuccessful despite an 
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enlarged urinary bladder, cats were assumed to suffer 
from rUO.
Study medication
Meloxicam or placebo was started 24 h after presenta-
tion. The 24 h window was planned for re-establishment 
of urine flow and to ensure that cats had a clinically nor-
mal volume and hydration status before entry into the 
study. In bottles that contained meloxicam the concen-
tration of the drug was 0.5 mg/ml. The dose of oral 
meloxicam was 0.1 mg/kg on day 1 and 0.05 mg/kg on 
the following 4 days (day 2–day 5). Therefore, all cats 
received 0.2 ml/kg of the suspension on day 1 and 0.1 
ml/kg of the suspension on day 2 to day 5. At the time of 
discharge from the hospital, owners were given written 
instructions to complete the 5 day treatment course with 
the study medication. The code was broken once in the 
middle of the study (after 24 cats) and in addition at the 
end of the study for the remaining cats.
Assessment of treatment success
The main parameter for treatment success was the occur-
rence of rUO within the first 7 days. Cats with rUO were 
censored at the time of rUO and excluded from further 
analysis. Results of the daily physical examinations 
(body temperature, respiratory rate, heart rate, abdomi-
nal pain, body weight, general demeanour, food intake, 
voiding behaviour and body weight) during hospitalisa-
tion and on recheck examination scheduled 10–14 days 
after discharge were recorded. General demeanour was 
assessed as normal or reduced (calm, depressed, aggres-
sive or defensive); pain on abdominal palpation was cat-
egorised as follows: clearly painful (tensed abdomen or 
displaying defence movements or vocalising upon 
abdominal palpation), mildly painful (discomfort on 
abdominal palpation, mild or moderately tensed abdo-
men) or not painful. Food intake was assessed as 
normal, reduced or anorexia.
On discharge from the hospital, owners were given a 
questionnaire for the assessment of the health status, 
voiding behaviour and macroscopic haematuria of their 
cats for the following 5 days. Owners graded the general 
condition, voiding behaviour (frequency, duration, pres-
ence of pain) and food intake of the cats on a 10 cm vis-
ual analogue scale. The left end of the scale was marked 
with findings expected in a normal cat, such as normal 
food intake and no straining to urinate, whereas the 
right end of the scale was marked with abnormal find-
ings such as no food intake, severe straining to urinate, 
frequently voiding outside the litter box. The distances 
from the left end of the scale to the marking were meas-
ured. Therefore, lower numbers indicated a more posi-
tive condition of the evaluated cat. A telephone interview 
was performed 3 months after initial presentation to see 
if cats had experienced recurrent episodes.
In addition, results of urinalyses performed on day 0, 
day 2 or day 3 and on recheck examination 10–14 days 
after discharge were evaluated.
Statistical analysis
Prism 5.04 software (GraphPad) was used for the statisti-
cal analysis. The Mann–Whitney U-test was used to 
evaluate differences in age and body weight between 
groups on presentation. The Kruskal–Wallis test and 
Dunn’s multiple comparison tests were used to evaluate 
for differences in the continuous parameters between 
groups at different time points and within groups 
between different time points. Results were regarded as 
significant if P <0.05. For investigation of categorical 
parameters (previous episodes of FLUTD, general 
demeanour, food intake, pain on abdominal palpation, 
macroscopic urine appearance, the degree of proteinu-
ria, the numbers of erythrocytes and leukocytes in the 
urine) between cats treated with meloxicam and cats 
treated with placebo, the χ2 test was performed.
Results
Cats and laboratory results on admission
Thirty-seven male cats with obstructive FIC were included 
in the study. There were no statistically significant differ-
ences between the treatment group and placebo group 
regarding age and body weight (Table 1). Cats in the 
meloxicam group had suffered from a significantly higher 
number of previous FLUTD episodes than cats of the pla-
cebo group (P = 0.046) and the proportion of cats with 
macroscopic haematuria was significantly higher in the 
meloxicam group (P = 0.049). However, at the time treat-
ment was started (day 1) equal numbers of cats in both 
treatment groups had macroscopic haematuria (Table 2). 
Analysis of haematology, serum chemistry, venous blood 
gas and urine revealed a significantly lower ionised cal-
cium (P = 0.040) in cats in the placebo group compared 
with cats in the meloxicam group on day 0 (Table 3). 
Urinalysis results revealed no significant differences 
between treatment groups at any time point (Table 4).
Evaluation of treatment success
Upon removal of the urinary catheter after 36–48 h, nine 
cats (four [22.2%] in the meloxicam group, five [26.3%] in 
the placebo group) suffered from rUO within the first 
week. Six rUOs (three cats from each group) were 
observed on day 2 and three (one meloxicam, two pla-
cebo) on day 3 (P = 1.000). Two more cats in the meloxi-
cam group had rUO on day 21 and day 79, and one cat in 
the placebo group on day 32. Cats in the meloxicam and 
placebo groups were presented for a recheck examination 
after a mean ± SD of 17.4 ±5.14 and 18.8 ± 4.33 days, 
respectively (P = 0.499). Results of physical examination 
findings are illustrated in Tables 2 and 5. There were no 
significant differences between treatment groups at any 
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Table 1 Signalment and history of 37 male cats with obstructive feline idiopathic cystitis
Meloxicam (n = 18) Placebo (n = 19) P value
Breed DSH 13 14 1.000
 Non-DSH 5* 5†  
Episodes First episode 10 14  
 Second episode 3 5 0.046
 ⩾3 episodes 5 0  
Mean ± SD age (years) 5.6 ± 2.23 6.1 ± 2.14 0.587
Median (range) age (years) 5.5 (2–11) 6.0 (1–13)  
Mean ± SD BM (kg) 6.2 ± 1.41 5.6 ± 1.05 0.135
Median (range) BM (kg) 6.3 (3.0–8.9) 5.5 (4.2–7.7)  
*One Persian, two Angora, one Maine Coon, one Norwegian Forest Cat mix
†One Persian, one Persian mix, one Siamese mix, one Chartreux mix, one Norwegian Forest Cat
DSH = domestic shorthair; BM = body mass
P <0.05 was considered significant (bold)
Table 2 Evaluation of 37 male cats with obstructive idiopathic cystitis during hospitalisation and at recheck examination 









meloxicam day 1 
vs 2, 3 and RC
P value placebo 












 1 Normal  15  14 0.693  
 Reduced 3 5  
 2 Normal  16  16 1.000 1.000 0.693
 Reduced 2 3  
 3 Normal  14  14 NA 0.238 0.057
 Reduced 0 0  
 RC Normal  12  13 NA 0.255 0.064











 Not painful 4 3  
 1 Clearly painful 4 5 0.450  
 Moderately painful 5 2  
 Not painful 9  11  
 2 Clearly painful 5 6 0.720 0.847 0.692
 Moderately painful 5 3  
 Not painful 7 8  
 3 Clearly painful 2 2 0.632 0.893 0.706
 Moderately painful 4 2  
 Not painful 7 9  
 RC Clearly painful 0  1 NA 0.019 NA
 Moderately painful 0 0  
 Not painful  11  10  
Food intake 0 Normal 6 4 0.235  
 Reduced 9 7  
 Anorexia 3 8  
 1 Normal 3 4 0.878  
 Reduced  10 9  
 Anorexia 5 6  
(continued)
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time point. Significantly improved food intake was 
reported at the time of recheck examination compared 
with day 1 in both treatment groups. The proportion of 
cats with macroscopic haematuria was significantly 
lower on recheck examination than on day 1 in both 
groups. No significant differences in general demeanour 
and pain on abdominal palpation within groups between 
day 1, day 2, day 3 were identified. However, there was 
a significant difference in pain on abdominal palpation 
in the meloxicam group between day 1 and the recheck 
examination (P = 0.019).
Regarding the results of the urinalysis, proteinuria 
and haematuria significantly improved during the study 
period. USG was significantly lower on day 2 or 3 than 
on day 0 and on recheck examination in both treatment 
groups (all P <0.05) (Table 5).
Questionnaires for all 14 cats in the meloxicam group 
and 13/14 cats in the placebo group without rUO were 
Table 3 Results of haematology, serum chemistry and venous blood gas from 37 male cats with obstructive feline 
idiopathic cystitis on day 0 (day of admission)
Meloxicam Placebo P value
Erythrocytes (× 109/l) 10.24 ± 1.14 9.91 ± 1.47 0.450
Haematocrit (l/l) 0.43 ± 0.04 0.41 ± 0.06 0.306
Leukocytes (× 106/l) 11.86 ± 4.75 13.62 ± 5.00 0.636
Creatinine (µmol/l) 244.20 ± 160.40 412.10 ± 466.70 0.438
Urea (mmol/l) 17.49 ± 8.79 24.04 ± 22.64 0.704
Glucose (mmol/l) 10.39 ± 2.84 8.41 ± 2.32 0.053
Bilirubin (µmol/l) 2.34 ± 1.20 2.55 ± 2.35 0.586
Alkaline phosphatase (U/l) 31.00 ± 10.25 28.00 ± 11.28 0.425
Alanine aminotransferase (U/l) 62.41 ± 18.89 77.89 ± 46.50 0.314
pH 7.28 ± 0.07 7.25 ± 0.12 0.673
Bicarbonate (mmol/l) 17.86 ± 2.31 17.13 ± 3.86 0.356
pCO2 (mmHg) 40.06 ± 7.30 38.68 ± 5.85 0.737
Potassium (mmol/l) 3.97 ± 0.62 4.91 ± 1.94 0.301
Ionised calcium (mmol/l) 1.22 ± 0.07 1.10 ± 0.21 0.040
Phosphate (mmol/l) 1.63 ± 0.31 2.04 ± 1.19 0.909
Sodium (mmol/l) 150.10 ± 3.43 147.50 ± 5.38 0.070
Chloride (mmol/l) 116.30 ± 4.03 112.10 ± 10.83 0.595
Data are mean ± SD









meloxicam day 1 
vs 2, 3 and RC
P value placebo 
day 1 vs 2, 3  
and RC
 2 Normal 3 6 0.539 0.771 0.670
 Reduced  11 9  
 Anorexia 3 4  
 3 Normal 2 5 0.404 0.606 0.440
 Reduced  10 7  
 Anorexia 2 2  
 RC Normal  10  12 NA <0.001 <0.001
 Reduced 0  1  













 2  9/18  11/18 0.738 0.500 1.000
 3  5/14  3/12 0.683 0.153 0.066
 RC  0/12   1/11 0.478 <0.001 0.007
The χ2 test was used for comparison of results between treatment groups at individual time points and between time points within groups  
P <0.05 was considered significant (bold)
NA = not applicable
Table 2 (Continued)
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available for analysis (Table 6). No significant differences 
between or within groups between time points were 
identified. The score means for all evaluated parameters 
were in the lower third of the scale for all parameters. 
After 5 days at home, however, none of the cats in both 
groups had a normal general demeanour or a normal 
food intake. Pollakiuria had completely resolved in three 
and four cats of the meloxicam and placebo group, 
respectively. Owners assessed five cats of the meloxicam 
group and seven cats of the placebo groups as still pain-
ful on voiding. Only three cats in the meloxicam group 
and one cat in the placebo group did not show any of the 
clinical sings pollakiuria, stranguria, painful voiding or 
periuria 5 days after discharge.
Four cats of each group had a culture-positive urine 
sample on day 2 with growth of ⩾103 colony-forming 
units/ml of a single organism. None of the cats with 
rUO had a positive culture at the time of urinary catheter 
removal on day 2.
Discussion
The present study investigated the use of meloxicam in a 
population of cats with obstructive FIC. The use of the anti-
inflammatory and analgesic drug meloxicam did not influ-
ence the incidence of rUO early after catheter removal and 
the severity of clinical signs in the present study. The recur-
rence rate within the first 7 days was 22.2% in the meloxi-
cam group and 26.3% in the placebo group, and the overall 
recurrence rate within 3 months was 33.3% and 31.5%, 
Table 4 Urinalysis results of 37 male cats treated with meloxicam and placebo on day 0 and day 2 or 3 and on recheck 
examination (RC)
Day Meloxicam Placebo P value P value meloxicam 
day 0 vs 2 or 3 and 
RC
P value placebo 






















(0–24 to > 
100/HPF)
0.231  
 2 or 3 25–100
(0–24 to >100/HPF)
25–100


















USG† 0 1.040 (1.018–1.048) 1.033  
(1.006–1.045)
NS  








Data are median (range). χ2 tests were used for investigation of categorical parameters (macroscopic haematuria, proteinuria, red blood cells 
[RBC]/high power field [HPF] and white blood cells [WBC]/HPF). For analysis of the urine specific gravity (USG) a Kruskal–Wallis test and 
Dunn’s multiple comparison tests were performed. P <0.05 was considered significant (bold)
*Protein analysed by dipstick analysis
†USG was determined by a hand refractometer
NA = not applicable; NS = not significant
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respectively. This is lower than previously reported in a pro-
spective study that evaluated the effect of intravesically 
administered buffered lidocaine with 58% of cats suffering 
from rUO,7 and higher than in three retrospective studies 
with recurrence rates of 16%, 22% and 24% up to 6 months 
after discharge from the hospital,6,10,14 and two prospective 
studies that investigated the effect of intravesically adminis-
tered glycosaminoglycans in cats with obstructive FIC, with 
recurrence rates of 18% and 19%.19,20 A longer duration of 
catheterisation (mean duration 32.1 h vs 21.6 h), the use of a 
smaller urinary catheter and the use of prazosin compared 
with phenoxybenzamine were associated with lower rates 
of rUO.10,14 In the present study, the indwelling urinary 
catheter was left in place for 48 h; therefore, a too-short 
duration of catheterisation should not have contributed to 
rUO. The protocol of the present study, as well as the 
protocol of the prospective study by Zezza et al,7 did not 
include α-sympatholytic drugs, which were part of the 
treatment protocol in the mentioned prospective study on 
pentosan polysulfate,20 and used in 84–97% of affected cats 
in the mentioned retrospective studies. This could contrib-
ute to higher rates of rUO in the present study. Most of the 
rUO occurred early after removal of the indwelling urinary 
catheter (day 2 or day 3) only shortly after the start of the 
study medication. This might be too early to expect an opti-
mal effect of the treatment. In addition, a significantly higher 
number of cats in the meloxicam group had previous epi-
sodes of FLUTD and five cats had already suffered from 
three or more clinical episodes, whereas no cat in the pla-
cebo group had had more than two episodes in the past. 
Therefore, a higher number of cats with a more severe and 
more chronic form of FIC in the meloxicam group might 
have obscured the beneficial effects of meloxicam in the pre-
sent study.
During hospitalisation, no difference in pain on 
abdominal palpation was identified. One limitation of the 
study is that pain was not assessed using a standardised 
pain-scoring system. It is possible that an effect of meloxi-
cam would have been identified with a more precise pain 
assessment. It could also be that the effect of meloxicam 
for this visceral pain is not strong enough and that these 
cats need more potent drugs such as morphine deriva-
tives. It is also possible that the dose of meloxicam used in 
the present study (0.1 mg/kg day 1, 0.05 mg/kg day 2) 
was not high enough. The used dosage on day 1 was 
lower than dosages recommended for cats for surgery-
associated pain,21 but doses on days 2–5 were in agree-
ment with the recommendation for oral administration of 
Table 5 Physical examination findings for 37 male cats with obstructive idiopathic cystitis during hospitalisation and at 
recheck examination (RC)
Day Meloxicam Placebo P value 
meloxicam vs 
placebo
P value meloxicam 
day 1 vs 2, 3 and 
RC
P value placebo 
day 1 vs 2, 3 and 
RC
Temperature (°C) 0 38.47 ± 0.67 38.13 ± 0.86 NS  
 1 38.85 ± 0.70 38.77 ± 0.41 NS  
 2 38.96 ± 0.47 38.66 ± 0.39 NS NS NS
 3 39.11 ± 0.52 38.80 ± 0.54 NS NS NS
 RC 38.67 ± 0.31 38.34 ± 0.44 NS NS NS
Heart rate/min 0 181.20 ± 31.55 170.20 ± 32.96 NS  
 1 200.40 ± 29.95 188.30 ± 33.58 NS  
 2 196.60 ± 24.96 178.90 ± 32.17 NS NS NS
 3 195.60 ± 26.90 193.10 ± 23.29 NS NS NS
 RC 191.10 ± 17.38 190.80 ± 29.64 NS NS NS
Respiratory 0 55.41 ± 24.83 37.21 ± 15.85  
rate/min 1 53.60 ± 32.37 40.00 ± 10.43 NS  
 2 42.60 ± 14.77 40.82 ± 9.65 NS NS NS
 3 46.22 ± 13.32 42.90 ± 13.03 NS NS NS
 RC 61.75 ± 26.99 57.50 ± 34.87 NS NS NS
Body weight (kg) 0 6.24 ± 1.41 5.62 ± 1.05 NS  
 1 6.24 ± 1.411 5.62 ± 1.02 NS  
 2 6.24 ± 1.380 5.61 ± 1.04 NS NS NS
 3 5.86 ± 1.27 5.44 ± 1.08 NS NS NS
 RC 5.98 ± 1.32 5.12 ± 0.93 NS NS NS
Data are mean ± SD. Cats with recurrent urethral obstruction were censored at the time of recurrent urethral obstruction. For comparison of 
parameters between groups at individual time points and between time points within groups the Kruskall–Wallis test and a Dunn’s multiple 
comparison test were performed. P <0.05 was considered significant
NS = not significant
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meloxicam.22 Even though meloxicam at this dose had no 
influence on the rate of rUO during the first week follow-
ing obstruction and made no difference regarding clinical 
recovery between groups and over time, it is still possible 
that its analgesic and anti-inflammatory effect is of benefit 
when combined with other groups of analgesics such as 
morphine derivatives.
All NSAIDs, including meloxicam, should be used 
with caution in patients with impaired hepatic, cardiac or 
renal function, and haemorrhagic disorders.23 In addition, 
hypotension, hypovolaemia, sodium depletion, high dos-
ages and inhalant anaesthesia are associated with a higher 
risk of renal toxicity.24 In the present study, the volume of 
IV fluid therapy was adjusted based on the degree of 
dehydration, plasma electrolyte concentrations and the 
severity of postobstructive diuresis, and led to a normal 
volume and hydration status of the cats when entering 
the study. In all cats with azotaemia on admission, creati-
nine decreased and 29/37 had creatinine in the normal 
range or only mildly elevated creatinine on day 1. A defi-
cient volume status, azotaemia not responsive to fluid 
therapy or severe blood loss via the urine would have 
prohibited the use of meloxicam. Proteinuria assessed by 
dipstick, as well as haematuria assessed on urine sedi-
ment, improved significantly in both treatment groups 
over the study period. As the decrease in proteinuria 
Table 6 Results of the questionnaire for days 1–5 after discharge from the hospital
Day Meloxicam Placebo P value 
meloxicam vs 
placebo
P value meloxicam 
day 1 vs 2, 3, 4 
and 5
P value placebo 
















 3 2.46 ± 2.27 2.22 ± 2.17 NS NS NS
 4 1.94 ± 2.01 2.22 ± 2.17 NS NS NS
 5 1.84 ±1.80 2.24 ± 2.43 NS NS NS
Food intake 1 3.74 ± 2.35 4.39 ± 3.05 NS  
 2 3.90 ± 2.86 4.32 ± 3.08 NS NS NS
 3 3.27 ± 2.51 3.02 ± 3.07 NS NS NS
 4 2.35 ± 2.15 2.08 ± 2.46 NS NS NS
 5 2.59 ± 2.44 2.32 ± 2.50 NS NS NS
Painful voiding 1 1.78 ± 2.88 2.29 ± 3.19  
 2 2.64 ± 3.54 1.68 ± 2.72 NS NS NS
 3 2.14 ± 3.22 1.87 ± 2.69 NS NS NS
 4 1.14 ± 2.63 1.24 ± 2.65 NS NS NS
 5 1.24 ± 2.63 1.43 ± 2.64 NS NS NS
Stranguria 1 2.37 ± 2.45 3.15 ± 3.55 NS  
 2 2.17 ± 2.87 2.85 ± 3.02 NS NS NS
 3 1.43 ± 2.36 2.35 ± 2.82 NS NS NS
 4 1.04 ± 2.47 1.97 ± 3.01 NS NS NS
 5 1.04 ± 2.45 2.21 ± 3.24 NS NS NS
Pollakiuria 1 3.41 ± 3.24 5.21 ± 3.50 NS  
 2 3.35 ± 3.16 3.31 ± 2.92 NS NS NS
 3 3.32 ± 3.45 3.42 ± 3.27 NS NS NS
 4 2.52 ± 3.07 2.78 ± 3.23 NS NS NS
 5 1.59 ± 2.65 2.83 ± 3.51 NS NS NS
Periuria 1 0.85 ± 2.51 1.23 ± 2.28 NS  
 2 1.32 ± 2.81 1.19 ± 1.99 NS NS NS
 3 1.17 ± 2.86 2.01 ± 2.66 NS NS NS
 4 1.19 ± 2.72 1.88 ± 3.14 NS NS NS
 5 0.76 ± 2.49 2.83 ± 3.16 NS NS NS
Owners assessed the parameters by markings on a 10 cm visual analogue scale. The left end of the scale was marked with findings expected 
in a normal cat such as normal food intake and no straining to urinate, whereas the right end of the scale was marked with abnormal findings 
such as no food intake, severe straining to urinate and frequently voiding outside the litter box. The distances from the left end of the scale to the 
marking were measured in cm. For comparison of parameters between groups and within groups at different time points the Kruskal–Wallis test 
and Dunn’s multiple comparison tests were applied. Significance was set at P <0.05
NS = not significant
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paralleled the decrease in haematuria, proteinuria was 
assumed to be postrenal in origin. In rats, certain NSAIDs 
(ketoprofen and indomethacin) have been shown to have 
an ulcerogenic effect,25 and haemorrhagic cystitis in 
humans has been documented in association with tiapro-
fenic acid, indomethacin, diclofenac, ketoprofen, nap-
roxen and piroxicam.26 As macroscopic and microscopic 
haematuria improved in both treatment groups, there was 
no hint for such a side effect of meloxicam in the present 
study.
Conclusions
The use of the non-steroidal anti-inflammatory drug 
meloxicam in cats with obstructive FIC did not influ-
ence the rate of rUO early after urinary catheter 
removal, and the hypothesis that anti-inflammatory 
therapy shortens the clinical episode and accelerates 
recovery could not be confirmed in this study popula-
tion. The persistence of clinical signs for >7 days in 
most of the cats indicates that for recovery from epi-
sodes of obstructive FIC prolonged symptomatic treat-
ment is warranted.
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